TME Pharma N.V. (ALTME.PA)
EUR 0.06
(1.1%)
EUR 0.06
(1.1%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.62 Million EUR | 53.25% |
| 2022 | -12.02 Million EUR | 9.33% |
| 2021 | -13.26 Million EUR | -129.97% |
| 2020 | -5.76 Million EUR | -46.12% |
| 2019 | -3.94 Million EUR | 9.59% |
| 2018 | -4.36 Million EUR | 7.67% |
| 2017 | -4.73 Million EUR | 44.99% |
| 2016 | -8.59 Million EUR | 42.02% |
| 2015 | -14.83 Million EUR | -12.64% |
| 2014 | -13.16 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.74 Million EUR | 0.0% |
| 2023 Q4 | -1.42 Million EUR | 0.0% |
| 2023 FY | -5.64 Million EUR | 53.1% |
| 2023 Q1 | -1.39 Million EUR | 67.64% |
| 2023 Q2 | -1.39 Million EUR | 0.0% |
| 2023 Q3 | -1.42 Million EUR | -2.01% |
| 2022 Q3 | -2.14 Million EUR | 72.27% |
| 2022 Q2 | -7.72 Million EUR | -100.0% |
| 2022 FY | -12.02 Million EUR | 9.33% |
| 2022 Q1 | -3.86 Million EUR | 48.49% |
| 2022 Q4 | -4.3 Million EUR | -100.75% |
| 2021 Q3 | -3.71 Million EUR | 38.42% |
| 2021 Q2 | -6.03 Million EUR | -100.0% |
| 2021 FY | -13.26 Million EUR | -129.97% |
| 2021 Q1 | -3.01 Million EUR | 23.99% |
| 2021 Q4 | -7.5 Million EUR | -101.94% |
| 2020 Q3 | -1.96 Million EUR | -1.74% |
| 2020 FY | -5.76 Million EUR | -46.12% |
| 2020 Q4 | -3.96 Million EUR | -102.09% |
| 2020 Q1 | -948.5 Thousand EUR | 50.68% |
| 2020 Q2 | -1.93 Million EUR | -103.48% |
| 2019 FY | -3.94 Million EUR | 9.59% |
| 2019 Q4 | -1.92 Million EUR | -88.71% |
| 2019 Q3 | -1.01 Million EUR | 55.7% |
| 2019 Q2 | -2.3 Million EUR | -127.05% |
| 2019 Q1 | -1.01 Million EUR | 2.03% |
| 2018 Q3 | -1.03 Million EUR | 18.84% |
| 2018 Q4 | -1.03 Million EUR | 0.0% |
| 2018 Q2 | -1.27 Million EUR | 0.0% |
| 2018 Q1 | -1.27 Million EUR | -12.74% |
| 2018 FY | -4.36 Million EUR | 7.67% |
| 2017 Q3 | -1.13 Million EUR | 8.8% |
| 2017 Q1 | -1.23 Million EUR | 23.31% |
| 2017 Q2 | -1.23 Million EUR | 0.0% |
| 2017 Q4 | -1.13 Million EUR | 0.0% |
| 2017 FY | -4.73 Million EUR | 44.99% |
| 2016 Q1 | -2.59 Million EUR | 26.01% |
| 2016 FY | -8.59 Million EUR | 42.02% |
| 2016 Q4 | -1.61 Million EUR | 0.0% |
| 2016 Q2 | -2.59 Million EUR | 0.0% |
| 2016 Q3 | -1.61 Million EUR | 37.72% |
| 2015 Q1 | -3.65 Million EUR | 0.0% |
| 2015 Q3 | -3.5 Million EUR | 4.13% |
| 2015 FY | -14.83 Million EUR | -12.64% |
| 2015 Q4 | -3.5 Million EUR | 0.0% |
| 2015 Q2 | -3.65 Million EUR | 0.0% |
| 2014 FY | -13.16 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -64.83% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 95.585% |
| Adocia SA | -17.62 Million EUR | 68.085% |
| Aelis Farma SA | -6.46 Million EUR | 12.955% |
| Biophytis S.A. | -14.33 Million EUR | 60.762% |
| Advicenne S.A. | -6.45 Million EUR | 12.901% |
| genOway Société anonyme | 2.06 Million EUR | 372.31% |
| IntegraGen SA | -183.77 Thousand EUR | -2960.347% |
| Medesis Pharma S.A. | -4.22 Million EUR | -32.976% |
| Neovacs S.A. | -6.9 Million EUR | 18.582% |
| NFL Biosciences SA | -4.43 Million EUR | -26.941% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -622.659% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -79.265% |
| Sensorion SA | -22.31 Million EUR | 74.792% |
| Theranexus Société Anonyme | -7.64 Million EUR | 26.423% |
| Valbiotis SA | -7.16 Million EUR | 21.453% |
| TheraVet SA | -2.17 Million EUR | -158.562% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 72.279% |
| argenx SE | -417.15 Million EUR | 98.652% |
| BioSenic S.A. | -7.04 Million EUR | 20.114% |
| Celyad Oncology SA | -8.45 Million EUR | 33.499% |
| DBV Technologies S.A. | -85.24 Million EUR | 93.403% |
| Galapagos NV | -88.26 Million EUR | 93.628% |
| Genfit S.A. | -26.58 Million EUR | 78.841% |
| GeNeuro SA | -14.35 Million EUR | 60.828% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 64.835% |
| Innate Pharma S.A. | -12.66 Million EUR | 55.608% |
| Inventiva S.A. | -102.7 Million EUR | 94.524% |
| MaaT Pharma SA | -19.94 Million EUR | 71.8% |
| MedinCell S.A. | -20.97 Million EUR | 73.19% |
| Nanobiotix S.A. | -26.77 Million EUR | 78.998% |
| Onward Medical N.V. | -35.46 Million EUR | 84.141% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -23.626% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 75.533% |
| Oxurion NV | -12.11 Million EUR | 53.559% |
| Pharming Group N.V. | -4.87 Million EUR | -15.257% |
| Poxel S.A. | -28.76 Million EUR | 80.448% |
| GenSight Biologics S.A. | -29.69 Million EUR | 81.061% |
| Transgene SA | -30.01 Million EUR | 81.261% |
| Financière de Tubize SA | -2.14 Million EUR | -162.317% |
| UCB SA | 604 Million EUR | 100.931% |
| Valneva SE | -82.08 Million EUR | 93.149% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 80.497% |